DDInter108 DDInter1652
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012.
Secukinumab is a fully human monoclonal IgG1/κ antibody against interleukin-17A (IL-17A), a proinflammatory cytokine implicated in various chronic immune-mediated inflammatory disorders, such as plaque psoriasis. By blocking the actions of IL-17A, secukinumab works to inhibit the pro-inflammatory pathways that drive immune-mediated inflammatory disorders. Following its first global approval in Japan in December 2014, secukinumab was approved by the European Commission on January 15, 2015, and by the FDA a few days after (January 21, 2015). It is currently approved to treat a number of chronic inflammatory conditions, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.[L39600,L42280,L48771]
Apixaban {u} (Compound) binds {v} (Gene) CYP2C8
Apixaban {u} (Compound) causes {v} (Side Effect) Incision site haemorrhage
Apixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capsicum
Apixaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Eliglustat
Apixaban {u} may lead to a major life threatening interaction when taken with {v} Desirudin
Apixaban {u} may lead to a major life threatening interaction when taken with {v} Trastuzumab emtansine
Apixaban (Compound) binds CYP2C8 (Gene)
Apixaban (Compound) causes Incision site haemorrhage (Side Effect)
Apixaban may cause a minor interaction that can limit clinical effects when taken with Capsicum
Apixaban may cause a minor interaction that can limit clinical effects when taken with Modafinil
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Apixaban may lead to a major life threatening interaction when taken with Desirudin
Apixaban may lead to a major life threatening interaction when taken with Trastuzumab emtansine